NVTA - Invitae Corporation

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by anotherdevilsadvocate, Dec 4, 2020.

  1. anotherdevilsadvocate

    anotherdevilsadvocate Well-Known Member

    Joined:
    Apr 3, 2016
    Messages:
    3,250
    Likes Received:
    2,624
    [​IMG]


    Invitae Corporation
    Healthcare | Diagnostics & Research | USA


    Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; and a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
     
  2. anotherdevilsadvocate

    anotherdevilsadvocate Well-Known Member

    Joined:
    Apr 3, 2016
    Messages:
    3,250
    Likes Received:
    2,624
    Holding the 50 sma
    [​IMG]

    Revenues were $69M (+21.6% in Q3), next Q4 forecast to be $96M (+45%).
    That would be $270M in 2020, and 2021 forecast is $514M (+90%).
    That's accelerating growth.
     
    T0rm3nted likes this.

Share This Page